Re‐evaluation of risk and oncological outcomes of resection of veins and arteries in the resection of pancreatic cancer

Abstract

BackgroundAdvances in chemotherapy have led to increasing major vascular resection during pancreatectomy which has been contraindicated due to high morbidity. This study aimed to verify the safety and oncological outcomes of vascular resection during pancreatectomy in the era of neoadjuvant therapy.MethodsData from patients who underwent surgery for pancreatic cancer at Seoul National University Hospital between 2001 and 2021 were reviewed. Clinicopathological outcomes were analyzed according vessel resection. A propensity‐score‐matched (PSM) analysis was performed to evaluate survival outcomes.ResultsOf 1596 patients, the proportion of those who underwent vascular resection increased from 9.2% to 23.4% over time divided into 5‐year intervals. There were no differences in major complications (15.6% vs. 13.0%; p = .266) and 30‐day mortality rate (0.3% vs. 0.6%; p = .837) between the vascular and nonvascular resection groups. After PSM, the vascular resection group demonstrated comparable survival outcome with the nonvascular resection group (5 year‐survival‐rate 20.4 vs. 23.7%; p = .194). Arterial resection yielded comparable survival outcome with nonvascular resection (5 year‐survival‐rate 38.1% vs. 23.7%; p = .138).ConclusionsAppropriate vascular resection―even arterial―is safe and effective in patients carefully selected for radical surgery in the era of neoadjuvant therapy. Further studies are needed to determine the optimal indication and method for vascular resection in patients with pancreatic cancer.